G Craig Wood1, Daniel Horwitz2, Christopher D Still1, Tooraj Mirshahi3, Peter Benotti1, Manish Parikh2, Annemarie G Hirsch4. 1. Geisinger Health System, Obesity Institute, Danville, PA, USA. 2. New York University School of Medicine/Bellevue Hospital Center, New York, NY, USA. 3. Geisinger Health System, Weis Center for Health Research, Danville, PA, USA. 4. Geisinger Health System, Department of Epidemiology and Health Services Research, Danville, PA, USA. aghirsch@geisinger.edu.
Abstract
OBJECTIVE: The objective of this study was to determine whether the DiaRem, a score that predicts type 2 diabetes (T2D) remission following roux-en-y gastric bariatric surgery (RYGB), also predicts remission following laparoscopic adjustable gastric banding (LAGB) and laparoscopic sleeve gastrectomy (LSG) in white and Hispanic patients. BACKGROUND: While bariatric surgery is highly effective in reversing insulin resistance, there are patients for whom surgery will not lead to remission. To date, there is no score for predicting remission following LAGB or LSG surgery. Additionally, there is little known about how to predict whether Hispanic patients will experience remission. METHODS: We conducted a retrospective cohort study of white and Hispanic patients with T2D who received bariatric surgery. There were 361 white and 130 Hispanic patients among whom 328 had RYGB surgery, 107 had LSG surgery, and 56 had LAGB surgery. We used age, diabetes treatment, and hemoglobin A1c to calculate DiaRem scores. Mann-Whitney U test was used to determine the association between DiaRem scores and remission. Area under the receiver operant curve (AUC) was used to assess the ability of the DiaRem to discriminate between patients who did and did not remit. RESULTS: The DiaRem was associated with partial remission in all surgery types for white and Hispanic patients (Mann-Whitney, p < 0.001). The DiaRem had moderate to high discriminant ability (AUC > 0.70) for all surgical and racial/ethnic groups. CONCLUSIONS: The DiaRem distinguishes between patients likely and unlikely to experience remission, informing expectations of patients making T2D treatment decisions.
OBJECTIVE: The objective of this study was to determine whether the DiaRem, a score that predicts type 2 diabetes (T2D) remission following roux-en-y gastric bariatric surgery (RYGB), also predicts remission following laparoscopic adjustable gastric banding (LAGB) and laparoscopic sleeve gastrectomy (LSG) in white and Hispanic patients. BACKGROUND: While bariatric surgery is highly effective in reversing insulin resistance, there are patients for whom surgery will not lead to remission. To date, there is no score for predicting remission following LAGB or LSG surgery. Additionally, there is little known about how to predict whether Hispanic patients will experience remission. METHODS: We conducted a retrospective cohort study of white and Hispanic patients with T2D who received bariatric surgery. There were 361 white and 130 Hispanic patients among whom 328 had RYGB surgery, 107 had LSG surgery, and 56 had LAGB surgery. We used age, diabetes treatment, and hemoglobin A1c to calculate DiaRem scores. Mann-Whitney U test was used to determine the association between DiaRem scores and remission. Area under the receiver operant curve (AUC) was used to assess the ability of the DiaRem to discriminate between patients who did and did not remit. RESULTS: The DiaRem was associated with partial remission in all surgery types for white and Hispanic patients (Mann-Whitney, p < 0.001). The DiaRem had moderate to high discriminant ability (AUC > 0.70) for all surgical and racial/ethnic groups. CONCLUSIONS: The DiaRem distinguishes between patients likely and unlikely to experience remission, informing expectations of patients making T2D treatment decisions.
Authors: Ida J Hatoum; Robin Blackstone; Tina D Hunter; Diane M Francis; Michael Steinbuch; Jason L Harris; Lee M Kaplan Journal: JAMA Surg Date: 2016-02 Impact factor: 14.766
Authors: Simona Panunzi; Lena Carlsson; Andrea De Gaetano; Markku Peltonen; Toni Rice; Lars Sjöström; Geltrude Mingrone; John B Dixon Journal: Diabetes Care Date: 2015-12-01 Impact factor: 19.112
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Christopher D Still; G Craig Wood; Peter Benotti; Anthony T Petrick; Jon Gabrielsen; William E Strodel; Anna Ibele; Jamie Seiler; Brian A Irving; Melisa P Celaya; Robin Blackstone; Glenn S Gerhard; George Argyropoulos Journal: Lancet Diabetes Endocrinol Date: 2014-01 Impact factor: 32.069
Authors: Linda S Geiss; Jing Wang; Yiling J Cheng; Theodore J Thompson; Lawrence Barker; Yanfeng Li; Ann L Albright; Edward W Gregg Journal: JAMA Date: 2014-09-24 Impact factor: 56.272
Authors: Wanda M Admiraal; Funda Celik; Victor E Gerdes; Ramsey M Dallal; Joost B Hoekstra; Frits Holleman Journal: Diabetes Care Date: 2012-09 Impact factor: 19.112
Authors: Kajsa Sjöholm; Lena M S Carlsson; Magdalena Taube; Carel W le Roux; Per-Arne Svensson; Markku Peltonen Journal: Diabetes Care Date: 2020-09-01 Impact factor: 19.112
Authors: Christopher D Still; Peter Benotti; Tooraj Mirshahi; Adam Cook; G Craig Wood Journal: Surg Obes Relat Dis Date: 2018-12-22 Impact factor: 4.734
Authors: Kristina H Lewis; David E Arterburn; Fang Zhang; Katherine Callaway; Jamie Wallace; Adolfo Fernandez; Dennis Ross-Degnan; James F Wharam Journal: Ann Surg Date: 2021-05-01 Impact factor: 13.787
Authors: Kajsa Sjöholm; Per-Arne Svensson; Magdalena Taube; Peter Jacobson; Johanna C Andersson-Assarsson; Lena M S Carlsson; Markku Peltonen Journal: Obes Surg Date: 2020-06-13 Impact factor: 4.129
Authors: Izabela A Karpińska; Joanna Choma; Michał Wysocki; Alicja Dudek; Piotr Małczak; Magdalena Szopa; Michał Pędziwiatr; Piotr Major Journal: Langenbecks Arch Surg Date: 2021-07-13 Impact factor: 2.895